Background: Bony metastases cause substantial morbidity and mortality from prostate cancer (PCa). The calcium sensing receptor (CaSR) is expressed on prostate tumors and may participate in bone metastases development. We assessed whether 1) common genetic variation in CaSR was associated with PCa risk and 2) these associations varied by calcium intake or plasma 25-hydroxyvitamin D (25(OH)D) levels. Methods: We included 1193 PCa cases and 1244 controls nested in the prospective Health Professionals Follow-up Study (1993)(1994)(1995)(1996)(1997)(1998)(1999)(2000)(2001)(2002)(2003)(2004). We genotyped 18 CaSR SNPs to capture common variation. The main outcome was risk of lethal PCa (n=113); secondary outcomes were overall (n=1193) and high-grade PCa (n=225). We used the kernel machine approach to conduct a genelevel multi-marker analysis and unconditional logistic regression to compute per-allele odds ratios (OR) and 95% confidence intervals (CI) for individual SNPs. Results: The joint association of SNPs in CaSR was significant for lethal PCa (p=0.04); this association was stronger in those with low 25(OH)D (p=0.009). No individual SNPs were associated after considering multiple testing; 3 SNPs were nominally associated (p<0.05) with lethal PCa with ORs (95% CI) of 0.65(0.42-0.99): rs6438705; 0.65(0.47-0.89)): rs13083990; and 1.55(1.09-2.20): rs2270916. The 3 non-synonymous SNPs (rs1801725, rs1042636, rs1801726) were not significantly associated; however, the association for rs1801725 was stronger in men with low 25(OH)D (OR(95%CI): 0.54(0.31-0.95)). There were no significant associations with overall or high-grade PCa. Conclusions: Our findings indicate that CaSR may be involved in PCa progression. Impact: Further studies investigating potential mechanisms for CaSR and PCa, including bone remodeling and metastases are warranted.
Introduction
When prostate cancer metastasizes, it shows a high propensity to metastasize to bone, especially to areas of high bone turnover (1, 2) . Bone metastases are difficult to treat and are a major cause of morbidity and mortality for patients with advanced prostate cancer, often causing severe pain, fractures, and death (1) . Calcium homeostasis and bone remodeling are hypothesized to be important factors in the development of bony metastases in prostate cancer.
Some epidemiologic studies have indicated that high intake of dietary calcium(3) and high serum calcium(4) may be associated with an increased risk of prostate cancer, particularly advanced or lethal disease. Moreover, increased parathyroid hormone (PTH) levels resulting in bone turnover promotes prostate bony metastases in animal studies (5) . Vitamin D deficiency promotes prostate cancer growth in bone in animal studies (6) and epidemiologic studies have shown that men with the lowest plasma 25-hyroxyvitamin D (25(OH)D) levels are at the greatest risk for lethal (metastatic or fatal) prostate cancer (7) (8) (9) .
A key regulator of calcium homeostasis is the calcium sensing receptor (CaSR), a transmembrane receptor that controls PTH levels through expression in the parathyroid gland. Initially, CaSR was described in tissue with clear roles in calcium homeostasis such as bone, parathyroid, and kidney. However, more widespread expression of CaSR has been discovered in other tissues, including prostate, breast and colon cancer tissue (10) (11) (12) (13) (14) and CaSR may also influence several tumor related processes independent of circulating calcium level regulation.
For example, in prostate and breast cancer cells CaSR has proliferative and anti-apoptotic effects, and may facilitate cell migration and bone metastases (15) (16) (17) . Additionally, CaSR expression has been shown to be upregulated through a vitamin D response element in the gene's promoter region (18) .
Genetic variants in CaSR may underlie some of the variability in its function. The only epidemiologic study, conducted in African American men, found that a non-synonymous SNP (Q1011E-rs1801726) common in the African American population was associated with advanced, but not overall prostate cancer (19) . Using prospectively collected data from the Health Professionals Follow-Up Study, we assessed whether genetic variation across CaSR was specifically associated with risk of lethal (distant metastatic or fatal) prostate cancer, given the biologic plausibility of its role in promoting metastatic disease. Moreover, we leveraged existing dietary and circulating biomarker data to assess whether these associations were modified by dietary and supplemental calcium intake or plasma 25(OH)D levels.
Materials and Methods

Study population
The Health Professionals Follow-up Study (HPFS) began in 1986 when 51,529 male health professionals aged 40 to 75 responded to a mailed questionnaire about their demographics, lifestyle, diet, and medical history (20). Medical and lifestyle information for this ongoing prospective cohort study was updated every 2 years via follow-up questionnaires; diet was updated every 4 years. The overall follow-up was over 94% and mortality assessment was greater than 98%. The current study was nested among the 18,018 (35%) of men who provided a blood specimen between 1993 and 1995. Specimens were processed within twenty-four hours of blood draw and plasma, erythrocytes and buffy coats were separated, aliquoted and stored in liquid nitrogen freezers (21) .
Incident cases of prostate cancer (diagnosed 1993-2004) were identified through the selfreported questionnaires or death certificates. Medical records and pathology reports were obtained from the majority (95%) of participants to confirm the diagnoses, and to abstract information on stage of disease (classified using the tumor, node and metastasis system and Gleason score (sum of major and minor components, 2-10). We used the pathologic stage and grade if available; otherwise we used clinical stage and grade. The cases were followed prospectively for mortality and metastases through March 2011. Deaths were identified via nextof-kin reports, mailings, and searches of the National Death Index, and confirmed by an Endpoints Committee through review of death certificates and medical records (90% of deaths and nearly all prostate cancer deaths were confirmed via medical record review). Medical record reviews were conducted blinded to exposure information. In addition, information on treatment and disease progression (e.g. metastases) was collected on all reported cases.
Men diagnosed with other types of cancer (except non-melanoma skin cancer) prior to blood draw were excluded from the study. We defined the main outcome of lethal prostate cancer as having distant metastases at diagnosis or development of distant metastases during follow-up, or prostate cancer specific death during follow-up through March 2011. We also assessed overall cancer, tumors characterized as advanced stage at diagnosis (T3b/T4, M1/N1(T1-T4) or lethal, and tumors characterized as high Gleason grade, defined as a Gleason pattern of 4+3 to 10. For the analysis, we also excluded men diagnosed with stage T1a microscopic focal prostate cancer because these tumors are generally indolent and are most susceptible to detection bias due to differential rates of undergoing surgery for benign prostatic hyperplasia.
We used a risk set sampling strategy to select eligible controls; controls were free of known prostate cancer at the time the case was diagnosed and reported having a PSA test after the date of blood draw (to ensure a more equal opportunity for prostate cancer detection as the majority of cases had received a PSA test for screening or as part of their diagnostic evaluation). We randomly selected one eligible control per case and matched on age (exact year of birth), PSA screening history prior to blood draw, and season, year and time of day of blood draw.
SNP selection and genotyping
Using the Tagger algorithm (22) All blood samples were identified with a research ID number only and matched casecontrol pairs were handled identically and assayed in the same batch in a blinded fashion. DNA was extracted from whole blood using a standard QIAmpTM kit (QIAGEN Inc., Chatsworth, CA) protocol and genotyping was performed using the Biotrove OpenArray SNP Genotyping Platform at the Harvard Medical School-Partners Healthcare Center for Genetics and Genomics.
Of the 18 genotyped SNPs, 17 had at least 95% genotype completion and 1 (rs7630625) had 92% completion. Multiple random blinded duplicate quality control samples were included and the concordance was 99.7%. If participants were missing genotype information, we imputed the values using the HapMap Phase III CEU data and the MACH imputation program (24) .
Calcium intake and plasma 25(OH)D
Dietary and supplement calcium intake were assessed through a validated semiquantitative food-frequency questionnaire collected every 4 years(20). We used energy-adjusted cumulative average intake until the date closest to, but before diagnosis to represent longer-term 7 calcium exposure. Because the relationship of calcium intake and fatal prostate cancer has been shown to be limited to the highest categories of calcium intake in our cohort(3), we used the top tertile of total calcium intake as the cut point for high calcium intake.
Plasma 25(OH)D was measured using radioimmunosorbant assay (Dr. Bruce Hollis) (25) in 4 separate batches with mean intrapair coefficients of variation from blinded quality control samples (5.4%, 5.6%, 14.8%, and 5.6%, for batches 1 to 4). are likely to be modest. Also, in contrast to methods that create a single genetic score from a set of proposed risk alleles, a benefit of the kernel machine is that it does not require a priori knowledge of directionality for the variants. In brief, the logistic kernel machine model treats each of the included SNPs as a random effect; desired covariates can be entered as fixed effects.
The null hypothesis that the variance of the SNP random effects is 0 (ie, that the SNPs individually or jointly are not associated with disease) can be tested using a score test. The kernel machine is computationally efficient compared with other methods that require permutation.
The in-depth mathematical details of the logistic kernel machine model have been described elsewhere (27, 28) .
Adjusted per-allele odds ratios (OR) and 95% confidence intervals (CI) of each individual SNP and lethal prostate cancer were assessed using unconditional logistic regression, adjusting for age at blood draw. We reported the nominal two-sided p-values for these analyses without adjusting for multiple testing; however, we also calculated a correction for multiple comparisons using a method (29) which takes into account the linkage disequilibrium within the set of SNPs being tested to calculate the effective number of independent tests. The 18 SNPs corresponded to 17 independent tests; consequently a p-value significance threshold of 0.003 controls the experiment-wide Type I error rate at the 0.05 level. We conducted stratified analyses to assess whether the association of any of the CaSR SNPs varied by high or low total calcium intake or plasma 25(OH)D levels by the cut points defined previously. We also 
Results
A total of 1193 incident prostate cancer cases and 1244 controls were included in this study; 113 of the cases were characterized as lethal, 158 were advanced stage or lethal, and 225
were Gleason-grade 4+3 or higher (Table 1) . Table 2 presents the global test for association between common genetic variation in CaSR and the per-allele ORs for each of the 18 SNPs and the main outcome lethal prostate cancer. Results from the logistic kernel machine including all 18 SNPs supported a significant association of common variation in CaSR and lethal prostate cancer (p=0.04). Additionally, this association across the gene with lethal prostate cancer was stronger among those with lower plasma 25(OH)D (p=0.007) compared to those with high plasma 25(OH)D (p=0.56) and lower total calcium intake (p=0.05) compared to those with high total calcium intake (p=0.41) (Tables   3a and 3b ).
Considering the SNPs individually, three SNPs (rs6438705, rs13083990, rs2270916) were nominally associated (p<0.05) with risk of lethal prostate cancer, but did not remain significant after considering multiple testing (Table 2 ). Although none of the three nonsynonymous SNPs (rs1801725, rs1042636, rs1801726) were significantly associated with lethal prostate cancer in the main effects analysis, rs1801725, the non-synonymous SNP with the most common MAF in Caucasian populations, had an OR=0.70; 95% CI: 0.46, 1.06; p-value=0.09.
Moreover, the association for rs1810725 and lethal prostate cancer was suggestively stronger for 
those with low plasma 25(OH)D (p-interaction=0.14) (Table 3a) . Tables 3a and 3b describe the individual SNP results with lethal prostate cancer by high and low plasma 25(OH)D and calcium intake. In particular, the relation between rs2270916 and risk of lethal prostate cancer appeared to be confined to men with low plasma 25(OH)D (p-interaction=0.02) (Table 3a) . Finally, although the main effect for rs7637874 and lethal prostate cancer was not statistically significant there was suggestive effect modification by total calcium intake (p-interaction-0.008) (Table 3b ).
Overall, results were consistent when we added advanced stage cancers (T3b/T4, M1/N1(T1-T4)) to the lethal cases (Table 4) . We found no significant associations for genetic variation in CaSR and risk of prostate cancer overall or high-grade disease (Table 4) . Sensitivity analyses conducted for the individual SNP results were consistent when we excluded individuals with missing genotypes (data not shown).
Discussion
To our knowledge, our study is the first epidemiologic study to specifically assess genetic variation across CaSR and lethal prostate cancer risk in Caucasian men. Using a global multimarker test, we observed a statistically significant joint association for variation across CaSR with lethal prostate cancer; this association was stronger in those with lower plasma 25(OH)D. We observed that three common variants in the CaSR gene were nominally associated with the lethal prostate cancer risk. Additionally, there was suggestive evidence that some of the individual associations varied by plasma 25(OH)D and total calcium intake. We did not observe an association with variation in CaSR and overall prostate cancer or high-grade prostate cancer.
Prostate cancer cells preferentially metastasize to bone, especially bone with higher remodeling activity (1 (31) . Additionally, activation of CaSR in tumor cells induces production of parathyroid hormone-related protein (PTHrP) and leads to bone resorption and further calcium release, which could create an environment favorable to bony metastases (2, 32) . CaSR activation has also been shown to have other oncogenic properties such as increased proliferation and decreased apoptosis.
Genome wide association studies (GWAS) of the CaSR and serum calcium have found that the variant allele of a non-synonymous SNP (rs1801725) and a SNP in high LD with rs1801725 (rs17251221) were associated with increased serum calcium(33, 34) magnesium, PTH, and decreased serum phosphate (34) and that these changes were consistent with a loss of function variant. This finding is intriguing in light of the suggestive protective association for those carrying the variant allele of rs1801725 and lethal prostate cancer observed in our data.
This association was stronger in those with low 25(OH)D levels. Since CaSR activation may lead to cancer progression, a variant resulting in a less active receptor is consistent with the observed protective association. Both calcium and vitamin D are important factors in calcium homeostasis and bone remodeling and low vitamin D may be a risk factor for lethal prostate cancer (7) . In addition, the CaSR gene contains a vitamin D response element that has been shown to upregulate its expression in some tissues (18) . Prior studies have found that high calcium intake(3) and low plasma 25(OH)D levels(9) are associated with lethal prostate cancer and the evidence that prostate cancers metastases favor bone with high remodeling activity (1) provide a basis for these relationships; however the mechanisms for these associations are still unclear. Our observations that CaSR is associated with lethal prostate cancer and the suggestive A case-only GWAS of prostate cancer comparing lethal to indolent cases did not report any significant findings for SNPs in the CaSR gene (35) . However, that study did not assess the joint effect of common variation across the entire CaSR gene and was not able to assess effect modification by calcium and plasma 25(OH)D. Finally, a GWAS study of advanced prostate cancer also did not identify any susceptibility loci in the CaSR gene (36) . Importantly, the definition of advanced cancers in that study combined both Gleason score (8-10) and stage (T3 or higher), while our study specifically focused on the more definitive outcome of lethal cancer.
Although Gleason score is an important predictor of prostate cancer progression, most cancers diagnosed at a high Gleason score will not progress to a lethal outcome and the overall positive predictive value of Gleason score for mortality is relatively low (37) . There is also evidence that including cancers that are stage T3a at diagnosis is not an ideal surrogate for lethal outcomes (38) . Our study did not find an association of variation in CaSR with prostate cancers defined by a Gleason of 7(4+3) or higher. Furthermore, when we analyzed prostate cancer cases based on a stage at diagnosis of T3a and higher we also did not find an association (data not shown). Thus, it appears that the findings in our study were primarily driven by lethal cancers.
It may be that CaSR acts independent of grade to drive progression to lethal cancers through influencing processes such as cell adhesion and metastases to bone. This is consistent with a study by Liao et al (2006)(16) 
Strengths and Limitations
Our study was restricted to Caucasian men of European descent and these findings may not be generalizable to other ethnicities that are known to have different allele frequencies (39) and different prostate cancer risks. Although we adjusted for multiple testing at the gene-level using a global test, we cannot rule out that our results could be due to chance. Our analyses for effect modification by calcium intake and plasma 25(OH)D were limited in power and could also be due to chance; however, the findings were biologically plausible and warrant further investigation in other cohorts for replication. Although a single measurement of plasma some batch-to-batch variation. However the rankings within each batch remained valid and we created batch-specific cut points in our analyses. Strengths of our study included the comprehensive linkage disequilibrium SNP selection method, the availability of dietary and supplement calcium intake data and plasma 25(OH)D levels, the ability to assess tumor characteristics by medical record review, and, importantly, the long follow-up for lethal outcomes.
Conclusions
In summary, our findings indicate that CaSR may play a role in prostate cancer progression perhaps via a mechanism involving bone remodeling and skeletal metastases. As bony metastases result in a high level of morbidity and mortality related to prostate cancer, gaining a better understanding the complex pathology of these bone lesions and the role of CaSR may lead to new insights and therapeutic strategies. 
